Review ArticleBarriers to Glaucoma Drug DeliveryGhate, Deepta MD; Edelhauser, Henry F. PhDAuthor Information Emory University Eye Center, Atlanta, GA Supported by NIH grants P-30-EY06360 and R24-EY017045 and an unrestricted grant from Research to Prevent Blindness. Reprints: Henry F. Edelhauser, PhD, Emory University Eye Center, 1365B Clifton Road, Atlanta, GA 30322 (e-mail: [email protected]). Received for publication September 11, 2006; accepted June 30, 2007 Journal of Glaucoma: March 2008 - Volume 17 - Issue 2 - p 147-156 doi: 10.1097/IJG.0b013e31814b990d Buy Metrics Abstract Topical medications remain the mainstay of glaucoma treatment. This review will aim to cover the pharmacokinetics of topically applied drops, the ocular barriers to drug delivery, and the role of ophthalmic drug formulation in enhancing drug delivery to the target tissue while minimizing side effects and increasing patient compliance. Recent advances in surgical techniques, therapeutic approaches, and material sciences have produced exciting new therapies for ocular diseases. The development of new vehicles and drug formulations that require less patient compliance is also discussed, as are the routes of drug delivery for neuroprotection. © 2008 Lippincott Williams & Wilkins, Inc.